[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588266":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":48,"collaborators":50,"id":54,"slug":20,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":20,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":20,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":75,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Tianjin Huanhu Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"UCAR T-cell group","EXPERIMENTAL","Universal allogeneic CD19\u002FBCMA CAR T-cells",[13],"Drug: UCAR T-cell",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","UCAR T-cell","Universal allogeneic anti-CD19\u002FBCMA CAR T-cells",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Jialing Wu","CONTACT","86-18622271026","wywjl2009@hotmail.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Guanen Zhou","86-13920273016","tjzge@163.com",[32],{"facility":5,"status":33,"city":34,"state":20,"zip":20,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Tianjin","China",{"type":37,"coordinates":38},"Point",[39,40],117.17667,39.14222,{"lat":40,"lon":39},[43,44,45,47],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"name":20,"role":24,"phone":20,"phoneExt":20,"email":30},{"name":23,"role":46,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"name":28,"role":46,"phone":20,"phoneExt":20,"email":20},{"type":46,"investigatorFullName":23,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Principal Investigator",[51],{"name":52,"class":53},"Shanghai Xiniao Biotech Co., Ltd.","INDUSTRY","100588266",false,"NCT06939166","Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19\u002FB Cell Maturation Antigen （CD19\u002FBCMA） in Patients With r\u002Fr Neurological Autoimmune Diseases","A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapsed \u002F Refractory Neurological Autoimmune Diseases","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Flow cytometry detected positive B cell CD19 or BCMA in the patient's peripheral blood.\n* Subjects with relapsed or refractory neurological autoimmune diseases, Including neuromyelitis optica spectrum disorders(NMOSD), myasthenia gravis(MG), multiple sclerosis(MS)，Autoimmune encephalitis(AE) and chronic inflammatory demyelinating Polyradiculoneuropathy(CIDP).\n* Female subjects of childbearing potential and male subjects with partners of childbearing potential must use medically approved contraception or abstinence during the study treatment period and for at least 6 months after the end of the study treatment; Female subjects of childbearing potential must have a negative Human chorionic gonadotropin (HCG) test within 7 days before study enrollment and not be lactating.\n* Willing to participate in this clinical study, sign an informed consent form, have good compliance, and cooperate with follow-up.\n\nExclusion Criteria:\n\n* Subjects with a history of severe drug allergies or allergic tendencies.\n* History of malignancy within five years.\n* Subjects with insufficient cardiac function.\n* Subjects who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA \\>the upper limit of detection; subjects positive for hepatitis C virus (HCV) antibody and peripheral blood HCV RNA; individuals positive for human immunodeficiency virus (HIV) antibody; individuals positive for syphilis testing.\n* Pregnant women or women planning to conceive.","ALL","18 Years",{"count":63,"type":64},12,"ESTIMATED","INTERVENTIONAL",[67],"EARLY_PHASE1","This is an open label, single-site, dose-escalation study in up to 12 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with universal CD19\u002FBCMA CAR T-cells.",[70,71,72,73,74],"Neuromyelitis Optica Spectrum Disorders","Myasthenia Gravis","Multiple Sclerosis","Chronic Inflammatory Demyelinating Polyradiculoneuropathy","Autoimmune Encephalitis",[76],"Universal Allogeneic CAR T-cells","2025-12-11",{"date":79,"type":80},"2025-12-15","ACTUAL",{"date":82,"type":80},"2025-06-17",{"date":84,"type":64},"2027-10",{"name":5,"class":6},1]